GLP-1 and Pregnancy: What Patients Need to Know

A thirty-four-year-old patient called the Columbus clinic last spring in a panic. She had been on semaglutide for nine months, had lost forty-two pounds, was finally feeling like herself again — and her at-home pregnancy test had two lines on it. She and her husband had not been actively trying. They had also not been actively preventing, because she had been told by a previous provider that her PCOS made conception unlikely without intervention. She wanted to know two things in the same breath: was the baby okay, and what did she do about the medication right now.

This is the conversation I have more often than the marketing for these drugs would suggest. GLP-1 receptor agonists are one of the most effective weight loss tools we have ever had access to. They are also restoring fertility in a population of women who had been told to plan around infertility — particularly women with PCOS, insulin resistance, or significant excess weight — and that restoration is happening faster than the patients or their providers have anticipated. The result is unplanned pregnancies on an active GLP-1 prescription, and a set of clinical decisions that need to be handled correctly.

Why GLP-1 medications restore fertility

The mechanism is not mysterious. Insulin resistance, central adiposity, and the hormonal disruptions that accompany them suppress ovulation in a meaningful percentage of reproductive-age women. PCOS is the most common phenotype but it is not the only one. The pattern is usually some combination of elevated fasting insulin, elevated free androgens, suppressed SHBG, and irregular or absent ovulation — a picture that is reinforced and worsened by excess weight and that often improves dramatically when the underlying insulin resistance is corrected.

GLP-1 therapy corrects insulin resistance through several mechanisms — improved beta cell function, reduced postprandial glucose load, weight loss, and visceral fat reduction. Within three to six months of starting a GLP-1, fasting insulin typically drops, SHBG rises, free testosterone falls back into a more physiologic range, and ovulatory cycles often resume in patients who had been anovulatory for years.

The fertility window I have seen most often opens around the three-to-six-month mark, frequently before the patient has lost the bulk of their target weight. A patient who has been told for a decade that she would need IVF to conceive can ovulate spontaneously and conceive within months of starting therapy. If contraception is not in place, an unplanned pregnancy is a predictable outcome.

I tell every reproductive-age woman this at the start of GLP-1 therapy. It is not a footnote. It is a counseling point that belongs in the same conversation as side effects and dosing.

What the data actually says about GLP-1 exposure in pregnancy

The honest answer is that human pregnancy data on semaglutide and tirzepatide are limited. Both medications are FDA-categorized to be discontinued during pregnancy and at least two months prior to planned conception based on the manufacturer's recommendation. Animal reproduction studies showed adverse developmental effects at exposures higher than the human therapeutic range, but those signals do not always translate cleanly to humans. The clinical registries that exist so far have not shown a clear teratogenic signal in early human exposures, but the sample sizes are too small to draw confident conclusions.

What that means in practice: there is no reassuring "this is fine" data, and there is no alarming "this is harmful" data. There is a recommendation to discontinue, an animal signal that warrants caution, and a clinical reality that pregnancy on a GLP-1 happens because the medication restores fertility faster than anticipated.

If a patient is exposed in early pregnancy, my approach is straightforward: stop the medication immediately, coordinate with her OB, refer to maternal-fetal medicine if her OB requests it, and do not panic. The exposures we have seen in registry data have not been associated with a clear pattern of adverse outcomes. The right next step is good prenatal care, not catastrophizing.

What I do clinically — preconception and during therapy

For any woman of reproductive age who is starting GLP-1 therapy, I have a structured conversation about contraception at the initial visit and document it. The options I discuss:

• Long-acting reversible contraception (LARC) — IUD or implant — is what I recommend for most patients who are not actively trying to conceive. It removes adherence as a variable. The IUD is particularly useful because slowed gastric emptying from GLP-1 therapy may reduce absorption of oral contraceptives, especially in the first weeks after a dose escalation. The clinical signal on this is small but it is real, and a non-oral method removes the question.
• Oral contraceptives are still appropriate for some patients, with the awareness that absorption may be variable in the first month or two of therapy. I tell oral contraceptive users to add a barrier method during the four weeks following any dose escalation.
• Barrier methods alone are inadequate for a population whose fertility is actively being restored. I tell patients this directly.
• No contraception, when the patient is actively planning a pregnancy: the medication should be discontinued at least two months before attempted conception per labeling. The relevant question becomes whether to use the GLP-1 to optimize metabolic health first, plan a discontinuation timeline, and conceive in the window after washout.

For patients with a history of PCOS or known insulin resistance who specifically want to use GLP-1 therapy as a fertility-optimization tool before conception, that is a legitimate plan. The sequence is: optimize on the medication for six to twelve months, discontinue, allow at least two months for washout, then attempt conception with the metabolic improvements still largely in place. I coordinate this with the patient's OB or reproductive endocrinologist when one is involved.

What to do if you become pregnant on a GLP-1

The clinical sequence is the same regardless of which GLP-1 you are on:

1. Stop the medication. Today, not next week. The half-life of semaglutide is about a week; tirzepatide is similar. The drug clears, but it clears slowly, and there is no reason to continue exposure once pregnancy is confirmed.
2. Contact your prescribing clinician. I want to know if one of my patients is pregnant. The conversation has implications for nutritional counseling, expected nausea pattern, and any handoff to the OB.
3. See your OB or establish OB care immediately. First trimester care, dating ultrasound, and standard prenatal labs.
4. Expect rebound appetite and the possibility of rapid weight regain. This is a real clinical issue. The medication has been suppressing appetite at a brain level; that suppression goes away over a few weeks. Combined with first-trimester nausea and food aversions in some patients, the eating pattern can be chaotic. Working with a nutrition resource during the transition helps.
5. Discuss any specific exposure concerns with maternal-fetal medicine if your OB recommends it. The current registry data do not warrant routine MFM referral but specific situations may.

What I look for at the workup before starting GLP-1 in a reproductive-age patient

When I evaluate a woman of reproductive age for GLP-1 therapy, my workup includes the standard metabolic panel — fasting insulin, HbA1c, fasting glucose, lipids, liver function, kidney function — and a focused reproductive picture: cycle history, prior pregnancy history, contraception in use, fertility goals over the next two years, and a baseline sex hormone panel including SHBG and free testosterone if there is any clinical signal of PCOS or hyperandrogenism.

I also ask explicitly whether the patient has been told she has fertility limitations and whether she has been planning around that. The answer changes my contraception counseling significantly. Patients who have been told for years that they are infertile have often stopped using contraception. Those are exactly the patients whose fertility is most likely to be restored on GLP-1.

The conversation about hormone optimization often runs in parallel. PCOS, insulin resistance, and suboptimal sex hormone status are commonly the same picture viewed from three angles. Treating only one angle frequently underperforms compared to treating the whole pattern.

The concrete next step

If you are on a GLP-1 and you are reproductive-age, the next step is making sure your contraception strategy is matched to the fact that this medication can restore your fertility faster than you expected. If you do not have a current method that meets that standard, that conversation belongs at your next visit.

If you are considering starting a GLP-1 and you have not had this conversation yet, book a medical weight loss program consultation specifically. Tell the front desk you are reproductive-age and want the workup to include the reproductive piece. Bring your current contraception method, your cycle history, and any prior fertility workup you have had.

If you are on a GLP-1 right now and you have just gotten a positive pregnancy test, stop the medication today and call the clinic. Bring whatever pregnancy testing or dating you have when you come in. We will walk through the immediate steps, coordinate with your OB, and make sure the transition off the medication is handled cleanly.

This is a question that has clinical complexity, but it has a clear path forward in every scenario. The right time to think about it is before the situation forces the question, not after.

TW

Travis Woodley

MSN, RN, CRNP — Platinum Biote Provider — Founder, Revitalize

Travis spent 17+ years in high-acuity clinical medicine — emergency, cardiac ICU, and cath lab — before founding Revitalize. He is a Certified Platinum Biote hormone therapy provider, the published author of You're Not Broken — You're Unbalanced, and the founder of the Rebuild Metabolic Health Institute. His clinical writing reflects the same precision he brought to critical care: specific, honest, and built around what actually works.

Book a ConsultationCall (762) 261-3880

About Travis →More articles →Rebuild Institute →